Stock Track | Bionano Genomics Soars 29% After-Hours on Q1 Earnings Beat and Updated Outlook

Stock Track

May 15, 2025

Shares of Bionano Genomics (NASDAQ: BNGO) surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.

The company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million, though it represents a 25.88% decrease from the $8.77 million reported in Q1 2024. Bionano Genomics also highlighted a gross margin of 46% for the quarter.

Looking ahead, Bionano Genomics updated its full-year 2025 revenue outlook to a range of $26 million to $30 million, with second-quarter revenue projected between $6.3 million and $6.8 million. The company reiterated its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Additionally, Bionano reported that its cash runway has been extended into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1199615678"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199615678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199615678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 04:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199615678","market":"nz","top_or_hot":-1,"title":"Stock Track | Bionano Genomics Soars 29% After-Hours on Q1 Earnings Beat and Updated Outlook","media":"Stock Track","content":"<p>Shares of Bionano Genomics (NASDAQ: BNGO) surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.</p>\n\n<p>The company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million, though it represents a 25.88% decrease from the $8.77 million reported in Q1 2024. Bionano Genomics also highlighted a gross margin of 46% for the quarter.</p>\n\n<p>Looking ahead, Bionano Genomics updated its full-year 2025 revenue outlook to a range of $26 million to $30 million, with second-quarter revenue projected between $6.3 million and $6.8 million. The company reiterated its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Additionally, Bionano reported that its cash runway has been extended into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Soars 29% After-Hours on Q1 Earnings Beat and Updated Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Soars 29% After-Hours on Q1 Earnings Beat and Updated Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-15 04:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bionano Genomics (NASDAQ: BNGO) surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.</p>\n\n<p>The company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million, though it represents a 25.88% decrease from the $8.77 million reported in Q1 2024. Bionano Genomics also highlighted a gross margin of 46% for the quarter.</p>\n\n<p>Looking ahead, Bionano Genomics updated its full-year 2025 revenue outlook to a range of $26 million to $30 million, with second-quarter revenue projected between $6.3 million and $6.8 million. The company reiterated its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Additionally, Bionano reported that its cash runway has been extended into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"","article_id":"1199615678","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199615678","pubTimestamp":1747254761,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bionano Genomics  surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.The company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly ab","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"股票追踪Bionano Genomics因第一季度盈利超出预期和更新前景而盘后飙升29%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1},"content_text":"Shares of Bionano Genomics (NASDAQ: BNGO) surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.\nThe company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million, though it represents a 25.88% decrease from the $8.77 million reported in Q1 2024. Bionano Genomics also highlighted a gross margin of 46% for the quarter.\nLooking ahead, Bionano Genomics updated its full-year 2025 revenue outlook to a range of $26 million to $30 million, with second-quarter revenue projected between $6.3 million and $6.8 million. The company reiterated its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Additionally, Bionano reported that its cash runway has been extended into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}